Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) EBIT (2016 - 2025)

Sanara MedTech (SMTI) has disclosed EBIT for 15 consecutive years, with $8.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 974.51% year-over-year to $8.4 million, compared with a TTM value of $5.9 million through Sep 2025, up 252.15%, and an annual FY2024 reading of -$6.7 million, down 59.32% over the prior year.
  • EBIT was $8.4 million for Q3 2025 at Sanara MedTech, up from -$31348.0 in the prior quarter.
  • Across five years, EBIT topped out at $8.4 million in Q3 2025 and bottomed at -$3.4 million in Q4 2021.
  • Average EBIT over 5 years is -$1.1 million, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw EBIT plummeted 300.49% in 2021, then soared 974.51% in 2025.
  • Year by year, EBIT stood at -$3.4 million in 2021, then rose by 8.48% to -$3.1 million in 2022, then surged by 92.76% to -$225995.0 in 2023, then tumbled by 65.88% to -$374884.0 in 2024, then soared by 2331.48% to $8.4 million in 2025.
  • Business Quant data shows EBIT for SMTI at $8.4 million in Q3 2025, -$31348.0 in Q2 2025, and -$2.1 million in Q1 2025.